BioCentury: Amyndas developing super compstatins for complement-mediated disorders

February 10, 2014

On February 10, 2014, in the article entitled “Amyndas: Complement shutdown,” Amyndas Pharmaceuticals was presented in BioCentury as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders that could be more potent than other complement inhibitors.

To read article:


Comments are closed.